Objective-Chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease that is distinct from pulmonary arterial hypertension (PAH). Although CTEPH is characterized by obstruction of major pulmonary artery because of chronic thrombus, it remains unclear whether CTEPH is associated with prothrombotic condition. Approach and Results-In addition to conventional markers, GTP-bound levels of Rap1, RhoA, RalA, Rac1, and Ras in platelets, which are implicated for platelet activation, were measured in patients without pulmonary hypertension (non-PH, n=15), patients with PAH (n=19), and patients with CTEPH (n=25). Furthermore, the responsiveness to ex vivo thrombin stimulation was also evaluated. 
C hronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease that is distinct from pulmonary arterial hypertension (PAH) including idiopathic pulmonary artery hypertension and collagen disease-related pulmonary hypertension in the Dana Point Classification. 1 CTEPH is characterized by obstruction of the major pulmonary arteries because of organized thrombus and distal pulmonary vasculopathy. 2, 3 Usually, the severity of CTEPH is gradually accelerated without drastic embolic events, 4 causing elevated pulmonary vascular resistance, increased pulmonary arterial pressure, and finally right heart failure and death.
There are 2 systems for hemostasis and thrombosis in our body: one is the coagulation system and the other is the platelet system. As the final product of the activated coagulation system by a series of protease cascade of coagulation factors, fibrin clot is formed. On the other hand, activated platelets secrete granules containing bioactive substances such as ADP and P-selectin, aggregate each other mediated by activated integrin αIIbβ3 (GPIIb/IIIa). These cellular functions are regulated by intracellular molecular switches such as small GTPases. It has been demonstrated that Rap1B 5 and RhoA 6,7 regulate aggregation while Rab27 8 and Ral 9 control granule secretion. Furthermore, RhoA 10, 11 and Rac1 12 are implicated in sharp change through the regulation of cytoskeletal reorganization.
Although CTEPH is considered as a thromboembolic disorder, it remains unclear whether it is associated with prothrombotic condition. The association of coagulation states with CTEPH has been shown only in specific conditions such as lupus anticoagulant/antiphospholipid antibodies. 13 However, most of patients with CTEPH are free from these disorders. The association between CTEPH and the activation of platelets is suggested based on the findings that platelet activating states such as splenectomy or thyroid hormone replacement are a risk factor of CTEPH in a few reports. 14, 15 Nevertheless, there have been few reports linking directly CTEPH to platelets activation, to date.
In the present study, we thus investigated whether the coagulation and platelet systems were activated in patients without pulmonary hypertension (non-PH), patients with PAH, and patients with CTEPH. In addition to the conventional markers reflecting the activation states of coagulation and platelets, we analyzed the activation levels of several small GTPases, such as Rap1, RhoA, RalA, Rac1, and Ras in platelets, because they were implicated as the novel factors for platelet activation. Furthermore, we also evaluated the responsiveness of platelets to ex vivo thrombin stimulation.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Baseline Characteristics
We confirmed the principles outlined in the Declaration of Helsinki. The study protocol was approved by the Ethical Committees of Tohoku University, and all patients provided written informed consent. The baseline characteristics of the enrolled patients are shown in Table 1 . This study enrolled the non-PH patients as control patients (n=15: hypertension n=7, hyperlipidemia n=5, hypertrophic cardiomyopathies n=2, and paroxysmal atrial fibrillation n=1), patients with PAH (n=19: idiopathic pulmonary hypertensions n=10, collagen diseases with pulmonary hypertension n=8, and congenital heart disease with pulmonary hypertension n=1), and patients with CTEPH (n=25). All patients with PAH and CTEPH and 10 among 15 patients of non-PH patients underwent cardiac catheterization in our institute from October, 2012, to June, 2013. The diagnosis of patients with PAH and CTEPH was made according to the European Society of Cardiology (ESC)/ European Respiratory Society (ERS) Guideline. 16 The ratios of diabetes mellitus, history of acute coronary syndromes, glomerular filtration rate, and obesity were comparable among 3 groups (Table 1) . No patients had undergone splenectomy. The drugs used for the enrolled patients are shown in Table 2 . The ratio of use of unfractionated heparin was comparable among 3 groups.
The hemodynamic parameters of the enrolled patients are shown in Table 3 17, 18 Although D-dimer and FDP levels tended to be increased in patients with PAH, these markers were not elevated in patients with CTEPH.
Platelet Preparation and Establishment of a Novel Method Evaluating the Activation States of Small GTPases in Platelets
Platelet rich plasma was prepared from the whole blood, and 1 mL platelet rich plasma was separated on Sepharose2B gel filtration column, where each 1 mL fraction was collected. The washed A, Platelet rich plasma was separated by Sepharose 2B gel filtration column, and each 1 mL fraction was collected as described in the Methods section in the online-only Data Supplement. In the fractions 2 and 3, washed platelets were eluted while serum was eluted after the fraction 5. B, The surface expression of P-selectin and PAC-1 binding of platelets with flow cytometric analysis in whole blood (left) and the isolated washed platelets (right). C, The washed platelets were stimulated by 0.25 U/mL thrombin at 30°C for indicated time, and various GTP-bound GTPases were analyzed by the pull down assay as described in the Methods section in the online-only Data Supplement.
platelets, appearing cloudy, were efficiently separated from the serum appearing yellow ( Figure 1A , fractions 2 and 3 compared with fraction 5). The analysis with flow cytometry revealed that there was no difference in P-selectin expression or PAC-1 binding between the platelets in whole blood and the washed platelets ( Figure 1B) , indicating that the platelets were not activated during this isolation process. Therefore, we used the washed platelets (fractions 2 and 3) in the following analysis of platelet activity.
To confirm that the pull down assays could evaluate activity of various GTPases (RhoA, RalA, Rac1, Rap1, and Ras), the washed platelets were stimulated with 0.25 U/mL thrombin at 30°C, and their time-dependent activations were analyzed by the pull down assay (see the Methods section in the onlineonly Data Supplement). Activities of all the GTPases were clearly elevated after the thrombin stimulation ( Figure 1C) , indicating that the pull down assay worked well.
Surface Expression Levels of P-Selectin and PAC-1 Binding Were Elevated in Platelets of Patients With CTEPH and PAH
We first analyzed activated states of platelets by flow cytometry. As shown in Figure 2A , the platelets of patients with PAH and CTEPH were highly activated compared with those of non-PH patients when evaluated for surface expression levels of P-selectin (a marker of granule secretion) and PAC-1 binding (a marker of GPIIb/IIIa activation). The P-selectinpositive platelets of non-PH patients, patients with PAH, and patients with CTEPH were 1.40% (0. CTEPH was 1.58% (1.08-2.11), 3.02% (2.03-3.54), and 2.64% (1.42-4.28), respectively ( Figure 3C ; non-PH versus PAH, P=0.02; non-PH versus CTEPH, P=0.048). However, Rap1, Rac1, and Ras were not activated in any group ( Figure 3D-3F) . Thus, in platelets, RhoA was significantly activated in patients with PAH and RalA in both patients with PAH and CTEPH compared with non-PH patients.
Reduced Expression of RalGAPβ in Platelets of Patients With CTEPH Might Mediate the Elevated RalA Activity
Activation levels of small GTPases are regulated by stimulatory regulators, guanine nucleotide exchange factors, and inhibitory regulators, GTPase activity proteins (GAPs). Although each GTPase generally has many kinds of its guanine nucleotide exchange factors and GAPs, only 2 molecules are known to have RalGAP activity in human cells that are RalGAP-1 (a heterodimer consisting of α1 and β subunits) and RalGAP-2 (that consisting of α2 and β subunits). Because complex formation of α and β subunits is essential for the GAP activity, as well as mutual protein stability, the RalGAP activity could be monitored by evaluating the amount of common RalGAPβ subunit. 19, 20 To address the cause of elevated activation of RalA in patients with PAH and CTEPH, we evaluated the expression levels of RalGAPβ subunit in platelets. As shown in Figure 4 , relative expression levels of platelets of non-PH patients (n=9), patients with PAH (n=11), and patients with CTEPH (n=17) were 1±0.76, 0.65±0.54, and 0.57±0.35 folds, relatively (Figure 4) . Thus, RalGAPβ in platelets tended to be decreased in patients with PAH and CTEPH. Reduced expression levels of RalGAP might cause elevated RalA activity.
Multivariate Regression Analysis for the Activation of Platelets in Patients With PAH and CTEPH
The activation of platelets is influenced by the drugs used for the treatment of PH, especially epoprostenol. 21 We analyzed whether the difference of the activation of RhoA and RalA or the ratio of P-selectin-and PAC-1-positive platelets was influenced by the drugs.
The multiple regression analysis with backward elimination stepwise variable selection was used to explore an optimal set of the drugs which involves starting with the initial set of PH drugs, including epoprostenol, oral prostaglandin I 2 analogue, endothelin receptor antagonist, and phosphodiesterase V inhibitor. The final models are listed in Table 4 .
The The ratio of P-selectin positive platelets was positively influenced by patients with CTEPH (3.315, P=0.005). The ratio of PAC-1 positive platelets was positively influenced by patients with CTEPH (10.122, P=0.010).
Thus, the RalA was activated in platelets of patients with CTEPH, and the platelets were more activated in patients with CTEPH than non-PH patients.
After the stimulation of thrombin, the ratio of PAC-1 positive platelets was positively influenced by patients with PAH (26.13, P=0.017) and CTEPH (30.90, P=0.004) . Thus, the platelets of patients with PAH and CTEPH were more hyperresponsive than non-PH patients to thrombin.
Platelets of Patients With CTEPH Were Hypersensitive to Thrombin Stimulation, Mediated by Protease-Activated Receptor 1
The responsiveness of platelets was evaluated after stimulation by 0.05 U/mL thrombin. P-selectin-positive platelets of the non-PH patients, patients with PAH, and patients with CTEPH were 2.09% (1.52-7.10), 9.75% Thrombin stimulation at 0.1 U/mL induced similar response to thrombin stimulation at 0.05 U/mL ( Figure I in the online-only Data Supplement). Thus, the platelets of patients with CTEPH were significantly activated by the thrombin stimulation than those of non-PH patients ( Figure 5A ).
Protease-activated receptor (PAR) 1 and PAR4 are known to mediate thrombin signaling in platelets. 22 PAR1 agonist induced similar response to thrombin in patients with PAH and CTEPH while PAR4 agonist hardly stimulated platelets ( Figure I in the online-only Data Supplement), suggesting that PAR1 played a dominant role in the hyperresponsive to thrombin stimulation in patients with PAH and CTEPH.
Thrombin Hyperresponsive Platelets in Patients With PAH and CTEPH Induced the Expression of Vascular Cell Adhesion Molecule-1 in Human Lung Microvascular Endothelial Cells
We evaluated functional relevance of the thrombin hyperresponsiveness of platelets in patients with PAH and CTEPH. Many chemical mediators would be released from activated platelets and induce the expression of inflammatory proteins such as vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells. 23 We examined the expression levels of VCAM-1 in human lung microvascular endothelial cells, after incubation with conditioned media of platelets of non-PH patients B A Figure 4 . The expression levels of RalGAPβ in the platelets. A, Representative results of the expression of RalGAPβ in the platelets of non-pulmonary hypertension (PH) patients, patients with pulmonary arterial hypertension (PAH), and patients with chronic thromboembolic pulmonary hypertension (CTEPH) . B, Quantification of the RalGAPβ expression levels in the platelets of non-PH patients (n=9), patients with PAH (n=11), and patients with CTEPH (n=17). The RalGAPβ expression levels were adjusted with β-actin levels, and the relative levels (mean±SD) were expressed using RalGAPβ expression levels in control group as 1.0. Adjusted for patients group, epoprostenol, oral prostaglandin I 2 analogue, endothelin receptor antagonist, and PDE V inhibitor. CTEPH indicates chronic thromboembolic pulmonary hypertension; PAH, pulmonary arterial hypertension; and PDE, phosphodiesterase.
(n=3), patients with PAH (n=4), and patients with CTEPH (n=3) activated with 0.05 U/mL thrombin for 20 minutes at 25°C. We also measured it after incubation with the same concentration of thrombin without platelets as the control. Relative expression levels of VCAM-1 by platelets of non-PH patients, patients with PAH, and patients with CTEPH to the controls were 2.35±0.85, 16.68±10.12, and 17.56±7.17 folds, respectively (non-PH versus PAH, P=0.06; non-PH versus CTEPH, P=0.02; Figure 6 ). Thus, the hyperstimulated platelets of patients with PAH and CTEPH have potentials to induce the VCAM-1 in the endothelial cells compared with non-PH patients. The VCAM-1 expression was adjusted with β-actin levels, and the relative expressive levels (mean±SD) were expressed using that VCAM-1 expression levels in the control group as 1.0. Statistical significance was determined with the Student t test.
Discussion
In the present study, we demonstrated for the first time that the platelets, but not the coagulation system, are activated in patients with CTEPH, by showing that (1) P-selectin-and PAC-1-positive platelets were increased, (2) RalA in platelets was activated, (3) platelets were hyperresponsive to thrombin stimulation, and (4) the D-dimer or FDP level was not elevated in patients with CTEPH compared with non-PH patients. CTEPH is a thrombosis-related disease. Although CTEPH is considered to link to venous thrombosis and pulmonary embolism, 2 our data indicated that platelets, but not coagulation system, are activated in patients with CTEPH. In the multivariate regression analysis, the activation of RalA was influenced by patients with CTEPH, but not PAH patients, whereas the activation of RhoA was influenced by patients with PAH, but not patients with CTEPH. Furthermore, elevation of PAC-1-positive platelets and P-selectin-positive platelets was detected in patients with CTEPH, but not in patients with PAH in the multivariate regression analysis, although pulmonary artery pressure was higher in patients with PAH than patients with CTEPH. Thus, elevation of RalA activity, PAC-1-positive platelets, and P-selectin-positive platelets would be rather specific to CTEPH and would not be dependent on high pulmonary artery pressure in CTEPH. These difference between PAH and CTEPH suggested the difference in the pathogenesis between PAH and CTEPH.
However, it cannot absolutely be excluded that the activated platelets of patients with CTEPH are secondary phenomena caused by surrounding circumstances such as pulmonary hypertension per se because platelets of patients with PAH were also activated in previous studies 24, 25 and this study. The platelet activation in patients with PAH is considered because of exposure to high shear in the pulmonary arteries and elevated levels of various cytokines. 26 Once the platelets are activated, they release serotonin and other chemical mediators that are involved in the progression of pulmonary hypertension. 27 In any case, activated platelets could contribute to the progression of the severity of CTEPH.
We showed that the platelets of patients with CTEPH exhibited higher levels of the surface expression of P-selectin and PAC-1 binding than those of non-PH patients in response to the ex vivo thrombin stimulation. Thus, the platelets of patients with CTEPH are not only in hyperactive states but also in hyperresponsive states to exogenous thrombin stimulation. Platelets of patients with PAH were also in hyperresponsive states to thrombin.
Many cytokines and endothelial dysfunction are involved in the pathogenesis of PH. 28 We showed that the hyperresponsiveness of platelets in patients with CTEPH and PAH induced VCAM-1 expression in endothelial cells, which was a key molecule of inflammation in endothelial cells. 23 These data suggest that the hyperresponsiveness of platelets in patients with CTEPH and PAH enhances inflammatory responses of the endothelial cells of pulmonary artery and contribute to the pathogenesis and progression of CTEPH and PAH.
Several small GTPases are also the key regulators of platelet functions. In the present study, we have successfully established the method to evaluate directly activated states of various small GTPases in platelets isolated from patients. With this method, we were able to demonstrate that RalA, which is implicated for granule secretion, was significantly activated in patients with CTEPH and PAH compared with non-PH patients and that RhoA, which is implicated for aggregation and shape change of platelets, was significantly activated in patients with PAH. RalA and RhoA in platelets could be sensitively activated compared with other G proteins. The difference in the mode of increased activity of small GTPases between CTEPH and PAH might reflect the different pathophysiology of these diseases. However, we found no increase in the activity of Rac1, Rap1, or Ras in platelets of patients with CTEPH, suggesting that the activities of these small GTPases are strictly regulated.
There are only 2 molecules, RalGAP-1 and RalGAP-2, which inactivate RalA. 19, 20 We showed that the expression levels of RalGAP tended to be reduced in the platelets of patients with PAH and CTEPH. These results suggest that RalGAP might be a molecule involved in the activation of RalA and the hyperresponsiveness of platelets in patients with CTEPH. It is possible that Ral-guanine nucleotide exchange factors contribute to the RalA activation. As for Ral-guanine nucleotide exchange factors, 6 molecules have been identified to date, 4 of which are activated directly by GTP-bound Ras and 2 of which contain Pleckstrin-homology domains and activated by elevated Ca 2+ concentration. 29 Thus, the stimulatory regulation of Ral activity is so complicated that further examination is necessary to determine their contribution. It is also the case for RhoA. Because both stimulatory and inhibitory regulations of RhoA are as complicated, even more complicated, as that of RalA, further investigation is required in the future.
To prevent the progression of CTEPH, patients with CTEPH are at present treated by anticoagulation treatment. Our data suggest that platelets in patients with CTEPH are activated. Therefore, antiplatelet treatment might be effective to prevent the progression of CTEPH. Further investigation is required in the future.
D-dimer and FDP are degraded products of fibrin fibers generated by fibrinolysis, reflecting the presence of newly generated fibrin fibers and plasmin activity. 17 Thus, these markers depend on newly produced fibrin clot and the activation of coagulation. In the present study, D-dimer and FDP levels were not elevated in patients with CTEPH compared with non-PH patients, a consistent finding with the previous study. 30 These results indicate that the coagulation system is at a basal level in the chronic stage of CTEPH.
Our study has several limitations. First, the number of the patients was relatively small. Second, because most of the patients were in New York Heart Association class I or II, we were unable to evaluate the association between platelet activation and clinical symptoms of patients with CTEPH.
In conclusions, the present study provides the first direct evidence that the platelets of patients with CTEPH are highly activated and more hyperreactive to thrombin stimulation compared with non-PH patients.
